CClinicalTrials.gg
Status unknownNCT04792671Updated Mar 11, 2021

Prevalence and Risk Factors of Women Mental Health Disorders

An observational study in Psychiatric Problem and Wolman Disease, sponsored by Assiut University. Status unknown. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-11.

Sponsored by Assiut University · Observational

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
200
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Perinatal major depressive disorder affects 20% of women, while perinatal anxiety affects 10% of women. Although pharmacological treatment has shown effectiveness, many pregnant women are concerned about potential adverse effects on the fetus, maternal-infant bonding, and child development.. On the other hand, Depressive disorder in women mainly occurs during the first year after childbirth. It takes many forms according to the onset, severity, and duration of the symptoms including; Postpartum blues (PPB), Postpartum depression (PPD), and Postpartum psychosis (PPP). Lack of access to mental health services during the perinatal period is a significant public health concern that may worse outcome.

So, we aimed to study prevalence of women mental health in Assiut governorate and evaluate possible risk factor for it

02

Conditions studied

  • Psychiatric Problem
  • Wolman Disease

Keywords

  • women
  • mental health
03

In context

Wolman Disease

35 studies on the registry are indexed under Wolman Disease; 5 are open to participants now.

This study's planned enrollment of 200 is close to the median of 200 across 19 observational studies indexed under Wolman Disease.

Browse Wolman Disease studies →

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

This is study will take part in the Assiut government primary health centres in community

Inclusion criteria

  • age 18 years -50 years.
  • No previous history of psychiatric, neurological or medical disease

Exclusion criteria

Exclusion Criteria:

  • intelligence equation less than 80
  • have history of psychiatric, neurological or medical disease
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Perinatal group

    females who are pregnancy

    Behavioral: Sociodemographic variables · Behavioral: Family affluence scale (FAS) · Behavioral: Edinburgh postnatal depression scale (EPDS) · Behavioral: Symptom Checklist 90 "SCL 90":

  • postpartum group

    female who get delivery(from day 1 up to 1 year)

    Behavioral: Sociodemographic variables · Behavioral: Family affluence scale (FAS) · Behavioral: Edinburgh postnatal depression scale (EPDS) · Behavioral: Symptom Checklist 90 "SCL 90":

Interventions

  • BehavioralSociodemographic variables

    age, residence, education of the mother and her husband, occupation of the mother and her husband, parity, gender, and age of the last baby.

  • BehavioralFamily affluence scale (FAS)

    a four-item measure of family wealth, has been developed in the WHO Health Behaviour in School-aged Children Study as an alternative measure.

  • BehavioralEdinburgh postnatal depression scale (EPDS)

    s a questionnaire originally developed to assist in identifying possible symptoms of depression in the postnatal period. It also has adequate sensitivity and specificity to identify depressive symptoms in the antenatal period and is useful in identifying symptoms of anxiety. more than 9 is clinically diagnosed

  • BehavioralSymptom Checklist 90 "SCL 90":

    is a 90-item questionnaire used to assess psychological problems. It is designed to evaluate a broad range of psychological problems and symptoms of psychopathology. More than 60 is considered clinically diagnosed

06

What researchers measure

Primary outcomes

  1. measure the prevalence of DSM 5 psychiatric disorders in perinatal and postnatal

    Time frame: through study completion, an average of 1 year

  2. measure of risk factor of DSM 5 psychiatric disorders in perinatal and postnatal

    Time frame: through study completion, an average of 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Sambrook Smith M, Lawrence V, Sadler E, Easter A. Barriers to accessing mental health services for women with perinatal mental illness: systematic review and meta-synthesis of qualitative studies in the UK. BMJ Open. 2019 Jan 24;9(1):e024803. doi: 10.1136/bmjopen-2018-024803. PubMed 30679296 ↗
  • Sheffield KM, Woods-Giscombe CL. Efficacy, Feasibility, and Acceptability of Perinatal Yoga on Women's Mental Health and Well-Being: A Systematic Literature Review. J Holist Nurs. 2016 Mar;34(1):64-79. doi: 10.1177/0898010115577976. Epub 2015 Apr 20. PubMed 25896571 ↗
  • Sharma V, Burt VK. DSM-V: modifying the postpartum-onset specifier to include hypomania. Arch Womens Ment Health. 2011 Feb;14(1):67-9. doi: 10.1007/s00737-010-0182-2. Epub 2010 Sep 25. PubMed 20872155 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04792671
Lead sponsor
Assiut University
Responsible party
Gellan Karamalllah Ramadan Ahmed (lecturer, resarcher OF Neurology and Psychiatry department, Assiut University) — Principal investigator
First posted
Mar 11, 2021
Start date
Mar 1, 2021 (estimated)
Primary completion
Sep 1, 2022 (estimated)
Completion
Sep 1, 2023 (estimated)
Last update
Mar 11, 2021

Study contacts

gellan Ahmed
Contact
gillankaram@aun.edu.eg
+201093663928

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion